Fig 1: Serum sIC levels were elevated in TILNs of DTC patients. (A) Serum concentration of CTLA‐4, LAG‐3, PD‐1, PD‐L1, and TIM‐3 in healthy controls (HC, n = 56) and DTC patients (DTC, n = 71). N.D., not determined. (B) Correlation between serum sIC levels and thyroid function results in DTC patients. The number in each cell in the upper right part of the matrix represents correlation coefficience, and the asterisk in the cell in the lower left part of the matrix represents a significant difference in p value. (C) Serum concentration of LAG‐3, PD‐1, PD‐L1, and TIM‐3 in DTC patients with CLNM (CLNM+, n = 34) or without CLNM (CLNM ‐, n = 37). (D) sIC levels in the supernatant of PBMCs of DTC patients with CLNM (CLNM+, n = 7) or without CLNM (CLNM ‐, n = 8). N.D., not determined. (E) sIC levels in extract from LNs of DTC patients without CLNM (CLNM ‐, n = 8), normal LNs of DTC patients with CLNM (CLNM+ nLNs, n = 7) or tumor‐involved LNs of DTC patients with CLNM (CLNM+ TILNs, n = 7). (F) TIM‐3 levels in extract from patient‐matched nLNs and TILNs (n = 5). *p < 0.05; **p < 0.01.
Fig 2: Identification of 2 novel anti-human LAG-3 mAbs (clones 4F4 and 4E12). (A) Western blot results showing that 4F4 and 4E12 could recognize the target protein bands of LAG-3. (B) Immunohistochemistry assay images showing that 4F4 and 4E12 could react with CHO/LAG-3. (C) Immunofluorescence assay images showing that 4F and 4E12 could react with CHO/LAG-3. (D) The binding ability of the antibody to immobilized LAG-3-Fc was detected via indirect ELISA. The results re-present the average absorbance at 450 nm. Abbreviations: CHO, Chinese hamster ovary; ELISA, enzyme-linked immunosorbent assay; LAG-3, lymphocyte activation gene-3; mAb: monoclonal antibody.
Fig 3: Progression-free survival (a) and overall survival (b) in patients with advanced renal cell carcinoma treated with mmune-oncology combination therapy based on immunohistochemical expression of LAG-3.
Fig 4: Association between sPD-L2 and PD-L2 expression in tumors (a). Association between sLAG-3 and LAG-3 expression in tumors (b). The representative immunohistochemical picture of PD-L2 expression in tumors (c). The representative immunohistochemical picture of LAG-3 expression in tumors (d).
Supplier Page from Abcam for Human LAG3 ELISA Kit